Study finds breast and ovarian cancer may have similar origins
While breast cancer is the most common cause of cancer death in women worldwide, ovarian cancer also is a significant source of mortality as the fifth leading cause of cancer death among women. These facts reflect the continued need for further understanding and innovation in cancer treatment.
A new study published in the International Journal of Molecular Sciences, describes a new concept of how these two cancers may evolve in a similar way and may eventually lead to more effective therapies for both.
"Though breast and ovarian cancer are distinctly clinically different, our analysis uncovered many overlaps, particularly with respect to genetic and epigenetic alterations," explained corresponding author Sibaji Sarkar, PhD, instructor of medicine at Boston University School of Medicine (BUSM). (Epigenetics is when genetically identical cells express their genes differently, causing different outcomes.)
BUSM researchers compared genetic, micro-environmental, stromal (connective tissue cells of any organ) and epigenetic changes common between breast and ovarian cancer cells, as well as the clinical relevance of these changes. They observed that selected genes including some oncogenes and tumor suppressor genes are similarly altered in these two types of cancers.
The study also presents a new model that explains how growth promoting genes could be epigenetically turned on and growth inhibiting genes could be epigenetically turned off in cancer cell formation.
"Both breast and ovarian cancers may have a similar origin. These similarities suggest that better understanding of this process will generate more effective chemotherapeutics, as well as strategies to circumvent drug resistance and cancer relapse," added Sarkar.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Chemists unlock the key to improving biofuel and biomaterial production - Spectroscopy method enables future opportunities for looking at complex biomolecules in different plants
Biocitech life science park welcomes Chem-X-Infinity and Spectralys Innovation - Two new arrivals add to Biocitech's success in attracting cutting-edge companies to the Paris life science park

Mechanism that reduces effect of cocaine on brain discovered
Novel Chemotherapy Agent Bendamustine Significantly More Effective First-Line Therapy Than Chlorambucil in CLL - Blood Marrow Normalised in 31% (Versus 2%) of Patients, With Manageable Side-Effects
Livatag follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients
